AUTISM BIOTECH LTD

autism-biotech.com

In the past few decades the prevalence of autism has risen more than thirtyfold from one in 2500 to one in 68 children. Much of this increase is likely due to changing diagnostic criteria. But whatever the cause, autism spectrum disorder has become one of today’s greatest paediatric health concerns.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

news image

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More

Medical

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

news image

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More

Industry Outlook

EXPANDING DIAGNOSTICS BUSINESS: SCHOTT SIGNS AGREEMENT TO ACQUIRE APPLIED MICROARRAYS INC.

Applied Microarrays Inc. | September 30, 2021

news image

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through th...

Read More

NCCN ONCOLOGY RESEARCH PROGRAM AND PUMA BIOTECHNOLOGY, INC. COLLABORATE TO RESEARCH ON NERATINIB IN VARIOUS CANCERS

National Comprehensive Cancer Network | October 16, 2020

news image

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a $2-million grant from Puma Biotechnology, Inc. Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of: ...

Read More
news image

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More
news image

Medical

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More
news image

Industry Outlook

EXPANDING DIAGNOSTICS BUSINESS: SCHOTT SIGNS AGREEMENT TO ACQUIRE APPLIED MICROARRAYS INC.

Applied Microarrays Inc. | September 30, 2021

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through th...

Read More
news image

NCCN ONCOLOGY RESEARCH PROGRAM AND PUMA BIOTECHNOLOGY, INC. COLLABORATE TO RESEARCH ON NERATINIB IN VARIOUS CANCERS

National Comprehensive Cancer Network | October 16, 2020

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research funding is supported by a $2-million grant from Puma Biotechnology, Inc. Projects may include pre-clinical, translational and clinical trials. They will focus on treatment of: ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us